MX354005B - Agonistas npr-b novedosos. - Google Patents

Agonistas npr-b novedosos.

Info

Publication number
MX354005B
MX354005B MX2014001528A MX2014001528A MX354005B MX 354005 B MX354005 B MX 354005B MX 2014001528 A MX2014001528 A MX 2014001528A MX 2014001528 A MX2014001528 A MX 2014001528A MX 354005 B MX354005 B MX 354005B
Authority
MX
Mexico
Prior art keywords
agonists
npr
new
new npr
unconventional
Prior art date
Application number
MX2014001528A
Other languages
English (en)
Spanish (es)
Inventor
Osterkamp Frank
Hawlisch Heiko
Hummel Gerd
Knaute Tobias
Reimer Ulf
Reineke Ulrich
Richter Uwe
Simon Bernadett
Specker Edgar
Woischnik Markus
R Hellberg Mark
Original Assignee
Shire Orphan Therapies Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43781057&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX354005(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Shire Orphan Therapies Gmbh filed Critical Shire Orphan Therapies Gmbh
Publication of MX354005B publication Critical patent/MX354005B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2242—Atrial natriuretic factor complex: Atriopeptins, atrial natriuretic protein [ANP]; Cardionatrin, Cardiodilatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Cardionatrin; Cardiodilatin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02—Linear peptides containing at least one abnormal peptide link
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
MX2014001528A 2009-09-25 2010-09-23 Agonistas npr-b novedosos. MX354005B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24596009P 2009-09-25 2009-09-25
PCT/US2010/049912 WO2011038061A2 (en) 2009-09-25 2010-09-23 Novel npr-b agonists

Publications (1)

Publication Number Publication Date
MX354005B true MX354005B (es) 2018-02-08

Family

ID=43781057

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2014001528A MX354005B (es) 2009-09-25 2010-09-23 Agonistas npr-b novedosos.
MX2017012681A MX370645B (es) 2009-09-25 2010-09-23 Agonistas npr-b novedosos.
MX2012003398A MX2012003398A (es) 2009-09-25 2010-09-23 Agonistas npr-b novedosos.

Family Applications After (2)

Application Number Title Priority Date Filing Date
MX2017012681A MX370645B (es) 2009-09-25 2010-09-23 Agonistas npr-b novedosos.
MX2012003398A MX2012003398A (es) 2009-09-25 2010-09-23 Agonistas npr-b novedosos.

Country Status (17)

Country Link
US (5) US8546523B2 (https=)
EP (1) EP2480247B1 (https=)
JP (3) JP5893561B2 (https=)
KR (3) KR20180049198A (https=)
CN (2) CN102548574B (https=)
AR (1) AR078445A1 (https=)
AU (1) AU2010298256B2 (https=)
BR (1) BR112012006579A2 (https=)
CA (1) CA2773949C (https=)
CL (2) CL2012000715A1 (https=)
MX (3) MX354005B (https=)
PH (1) PH12012500562A1 (https=)
RU (3) RU2636738C2 (https=)
TW (2) TWI625126B (https=)
UY (1) UY32902A (https=)
WO (1) WO2011038061A2 (https=)
ZA (3) ZA201201630B (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2510942T3 (en) 2005-04-07 2015-12-14 Cardiorentis Ag Use of natriuretic peptides for the treatment of heart failure
EP2054044B1 (de) * 2006-08-02 2014-07-23 Johannes Gutenberg-Universität Mainz Arzneimittel gegen lct-vergiftungen
EP2480247B1 (en) * 2009-09-25 2020-02-12 Shire Orphan Therapies GmbH Novel npr-b agonists
AR078446A1 (es) 2009-12-18 2011-11-09 Alcon Res Ltd Agonistas de npr-b. uso.
CN108653715A (zh) * 2011-12-16 2018-10-16 卡乐斯治疗公司 用于治疗视网膜病症和疾病的anp、bnp以及cnp相关肽及其衍生物的方法和用途
US20140213520A1 (en) * 2013-01-25 2014-07-31 Cardiorentis Ltd. Methods of treating cardiovascular indications
EP4067368A1 (en) 2016-06-01 2022-10-05 Athira Pharma, Inc. Compounds
EP3576770A1 (en) 2017-02-01 2019-12-11 Shire Human Genetic Therapies, Inc. Compounds and compositions for the treatment of ophthalmic disorders
EP3810082A1 (en) * 2018-06-19 2021-04-28 Cella Therapeutics, LLC Sustained-release drug delivery systems comprising an intraocular pressure lowering agent, a cnp compound, an npr-b compound, a tie-2 agonist, or neurotrophic agent for use for treating glaucoma or ocular hypertension
ES3034676T3 (en) * 2018-11-16 2025-08-21 Arcus Biosciences Inc Inhibitors of arg1 and/or arg2
IL298980A (en) * 2020-06-12 2023-02-01 Pharmain Corp C-type natriuretic peptides and methods thereof in treating acute lung injury
KR102677730B1 (ko) * 2023-03-27 2024-06-27 나인바이오팜 주식회사 지방 분해 효능을 갖는 펩타이드 및 이의 용도

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4757048A (en) 1985-11-05 1988-07-12 Biotechnology Research Associates J.V. Synthetic analogs of atrial natriuretic peptides
AU2927889A (en) * 1987-12-24 1989-07-19 California Biotechnology, Inc. Linear analogs of atrial natriuretic peptides
WO1990001940A1 (en) 1988-08-18 1990-03-08 California Biotechnology Inc. Atrial natriuretic peptide clearance inhibitors
CN1169573C (zh) 1998-09-28 2004-10-06 参天制药株式会社 用于治疗角结膜障碍的、包含作为活性组分的钠尿肽的泪液分泌促进剂或滴眼剂
US20040266673A1 (en) 2002-07-31 2004-12-30 Peter Bakis Long lasting natriuretic peptide derivatives
US6025198A (en) 1999-06-25 2000-02-15 Isis Pharmaceuticals Inc. Antisense modulation of Ship-2 expression
US6436703B1 (en) * 2000-03-31 2002-08-20 Hyseq, Inc. Nucleic acids and polypeptides
IL142118A0 (en) * 2001-03-20 2002-03-10 Prochon Biotech Ltd Method and composition for treatment of skeletal dysplasias
TWI231759B (en) 2001-06-27 2005-05-01 Alcon Inc Olopatadine formulations for topical administration
US7648962B2 (en) * 2002-11-26 2010-01-19 Biocon Limited Natriuretic compounds, conjugates, and uses thereof
US7297709B2 (en) 2003-05-22 2007-11-20 Abbott Laboratories Indazole, benzisoxazole, and benzisothiazole kinase inhibitors
ATE496060T1 (de) * 2004-07-15 2011-02-15 Univ Queensland Proteinartige verbindungen und anwendungen davon
TW200640443A (en) 2005-02-23 2006-12-01 Alcon Inc Methods for treating ocular angiogenesis, retinal edema, retinal ischemia, and diabetic retinopathy using selective RTK inhibitors
WO2007034498A1 (en) 2005-09-26 2007-03-29 Compugen Ltd. Atrial natriuretic peptide (anp) splice variants and methods of using same
EP1951277A2 (en) * 2005-10-14 2008-08-06 Biorexis Pharmaceutical Corporation Natriuretic peptide modified transferrin fusion proteins
US7795221B2 (en) * 2006-03-30 2010-09-14 Palatin Technologies, Inc. Linear natriuretic peptide constructs
EP2001518B1 (en) * 2006-03-30 2013-07-10 Palatin Technologies, Inc. Cyclic natriuretic peptide constructs
AR069409A1 (es) * 2007-11-21 2010-01-20 Biomarin Pharm Inc Variantes de peptidos natriureticos de tipo c
EP2480247B1 (en) 2009-09-25 2020-02-12 Shire Orphan Therapies GmbH Novel npr-b agonists
US8551938B2 (en) 2009-09-25 2013-10-08 Alcon Research, Ltd. NPR-B agonists
AR078446A1 (es) 2009-12-18 2011-11-09 Alcon Res Ltd Agonistas de npr-b. uso.

Also Published As

Publication number Publication date
CL2017001190A1 (es) 2017-12-01
KR101768661B1 (ko) 2017-08-16
KR101854820B1 (ko) 2018-05-04
RU2015124607A (ru) 2015-12-10
TWI577384B (zh) 2017-04-11
CA2773949C (en) 2020-11-03
AU2010298256B2 (en) 2015-08-13
WO2011038061A3 (en) 2011-07-28
EP2480247A2 (en) 2012-08-01
JP2015131856A (ja) 2015-07-23
MX2012003398A (es) 2012-04-10
US20170313743A1 (en) 2017-11-02
KR20180049198A (ko) 2018-05-10
BR112012006579A2 (pt) 2016-11-22
ZA201702958B (en) 2018-08-29
CN105732767A (zh) 2016-07-06
US9169293B2 (en) 2015-10-27
RU2557290C2 (ru) 2015-07-20
US9745344B2 (en) 2017-08-29
KR20120091110A (ko) 2012-08-17
TWI625126B (zh) 2018-06-01
ZA201201630B (en) 2014-05-28
MX370645B (es) 2019-12-19
PH12012500562A1 (en) 2012-10-22
CA2773949A1 (en) 2011-03-31
CN102548574B (zh) 2016-03-23
ZA201401625B (en) 2018-08-25
AU2010298256A1 (en) 2012-04-12
US20130345394A1 (en) 2013-12-26
CN102548574A (zh) 2012-07-04
KR20170094564A (ko) 2017-08-18
US8546523B2 (en) 2013-10-01
AR078445A1 (es) 2011-11-09
EP2480247A4 (en) 2013-09-04
US20110077381A1 (en) 2011-03-31
WO2011038061A2 (en) 2011-03-31
JP6211032B2 (ja) 2017-10-11
TW201630619A (zh) 2016-09-01
RU2012116531A (ru) 2013-10-27
US20180334477A1 (en) 2018-11-22
US9982016B2 (en) 2018-05-29
US20160194357A1 (en) 2016-07-07
RU2636738C2 (ru) 2017-11-28
RU2017139870A3 (https=) 2019-05-16
JP2013505937A (ja) 2013-02-21
UY32902A (es) 2011-02-28
TW201110974A (en) 2011-04-01
CL2012000715A1 (es) 2012-11-30
JP5893561B2 (ja) 2016-03-23
EP2480247B1 (en) 2020-02-12
JP2017137362A (ja) 2017-08-10
RU2017139870A (ru) 2019-05-16
US10196423B2 (en) 2019-02-05

Similar Documents

Publication Publication Date Title
MX354005B (es) Agonistas npr-b novedosos.
ES2691070T3 (es) Péptidos antiinflamatorios y composición que comprende los mismos
BR112012024373A2 (pt) peptídeos e métodos para sua preparação e uso.
PE20141672A1 (es) FORMULACION PARA ANTICUERPO ANTI-alfa4�7
UA118167C2 (uk) Пептид та його застосування
EP2185170A4 (en) COMPOSITION FOR PEPTIDE ANALOGUE WITH LONG-TERM EFFECT
EA201190292A1 (ru) Улучшенная композиция реконструированных сурфактантов, содержащая аналоги сурфактантного белка в (sp-b) и сурфактантного белка с (sp-c)
UY31597A1 (es) Nuevos derivados de insulina con perfil tiempo/accion extremadamente retardado
CL2012002884A1 (es) Polipeptido que comprende un dominio decimo de fibronectina de tipo iii que se unen a la proteina covertasa subtilisina kexina tipo q ( pcsk9); composicion farmacéutica que comprende dicho polipeptido.
CR20120139A (es) Polipeptidos para union al receptor para productos finales de glicosilacion avanzada asi como composiciones y metodos que implican a los mismos
CO6311108A2 (es) Analogos de insulina en los cuales el extremo de la cadena b consiste en un residuo aminoácido, el residuo de aminoácido n-terminal de la cadena a de la insulina es un residuo lisina o arginina, la posición a8 del aminoácido está ocupada por un resid
JO3400B1 (ar) مركب صيدلاني من كاربيتوسين
EA201390182A1 (ru) Соединения-агонисты рецептора glp-1, содержащие стабилизированные области
MY151985A (en) Dental wipe
MX366935B (es) Peptidos intestinales vasoactivos modificados.
MX336715B (es) Purificacion de iduronato-2-sulfatasa.
PH12013500167A1 (en) Polypeptidic tyrosinase inhibitor
CL2018003319A1 (es) Compuestos de mic-1 y usos de estos.
WO2011146922A3 (en) Materials and methods for treatment of inflammation
EP2819682A4 (en) TOPICAL GELS WITH ALPHA CONNEXIN C TERMINALS PEPTIDES (ACT)
MX2015002994A (es) Peptidos de inhibidores obtenidos del receptor desencadenante expresado en celulas mieloides de tipo 1 (trem-1) y transcrito similar a trem 1 (tlt-1) y usos de los mismos.
CO7131365A2 (es) Factores de coagulación de acción prolongada y métodos de producción de los mismos
ES2570458T3 (es) Peptidomiméticos fijados sobre una matriz con actividad moduladora de CXCR7
EA201290542A1 (ru) Модифицированные свиные соматотропиновые полипептиды и их применение
DK2207790T3 (da) Biologisk aktive C-terminalt argininholdige peptider